Ribosomal protein 34 (RPL34) is a highly conserved protein belonging to the 60S large subunit of mammalian ribosomes that has been found to be dysregulated in a variety of human tumors. However, there are limited results that illuminate the role and expression profiles of RPL34 in hilar cholangiocarcinoma (HCCA). RPL34 expression was detected in human HCCA by immunohistochemistry. The relationship of RPL34 expression with clinical outcomes was evaluated by univariate and multivariate analyses. The effect of RPL34 on cell migration and tumor growth was detected after silencing endogenous RPL34 expression. RPL34 was overexpressed in HCCA compared with normal tissue samples and correlated significantly with regional lymph node metastasis and poorly/undifferentiated tumors. Patients with high RPL34 expression had a shorter time to recur and a poorer outcome than those without RPL34 expression. Silencing RPL34 inhibited cell proliferation and migration in vitro and upregulated E-cadherin. Silencing RPL34 also attenuated tumor growth in vivo. Our findings suggested that RPL34 might serve as a promising prognostic biomarker and a potential therapeutic target for the treatment of HCCA.

中文翻译：

---

核糖体蛋白L34是肝门胆管癌的潜在预后生物标志物和治疗靶标

核糖体蛋白34（RPL34）是一种高度保守的蛋白，属于哺乳动物核糖体的60S大亚基，已发现在多种人类肿瘤中表达异常。然而，有限的结果阐明了RPL34在肝门胆管癌（HCCA）中的作用和表达谱。通过免疫组织化学在人HCCA中检测到RPL34表达。RPL34表达与临床结局的关系通过单因素和多因素分析进行​​评估。沉默内源性RPL34表达后，检测到RPL34对细胞迁移和肿瘤生长的影响。与正常组织样本相比，RPL34在HCCA中过表达，并且与区域淋巴结转移和肿瘤差/未分化明显相关。与没有RPL34表达的患者相比，RPL34表达高的患者复发时间短且预后较差。沉默RPL34在体外抑制细胞增殖和迁移，并上调E-钙粘蛋白。使RPL34沉默还可以减弱体内肿瘤的生长。我们的发现表明，RPL34可能作为有前景的预后生物标志物和潜在的治疗HCCA的治疗靶标。